Instadose Pharma Corp. (INSD)

USD 0.0

(0.0%)

Operating Income Summary of Instadose Pharma Corp.

Instadose Pharma Corp.'s latest annual operating income in 2023 was - USD , up 100.0% from previous year.
Instadose Pharma Corp.'s latest quarterly operating income in 2024 Q1 was - USD , down 0.0% from previous quarter.
Instadose Pharma Corp. reported an annual operating income of -588.71 Thousand USD in 2022, down -1667.18% from previous year.
Instadose Pharma Corp. reported an annual operating income of -33.31 Thousand USD in 2021, down -43.14% from previous year.
Instadose Pharma Corp. reported a quarterly operating income of - USD for 2023 Q3, down 0.0% from previous quarter.
Instadose Pharma Corp. reported a quarterly operating income of - USD for 2023 FY, up 100.0% from previous quarter.

Annual Operating Income Chart of Instadose Pharma Corp. (2023 - 2017)

Historical Annual Operating Income of Instadose Pharma Corp. (2023 - 2017)

Year	Operating Income	Operating Income Growth
2023	- USD	100.0%
2022	-588.71 Thousand USD	-1667.18%
2021	-33.31 Thousand USD	-43.14%
2020	-23.27 Thousand USD	1.13%
2019	-23.54 Thousand USD	26.32%
2018	-31.94 Thousand USD	-1546.75%
2017	-1940.00 USD	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	- USD	0.0%
2023 Q3	- USD	0.0%
2023 FY	- USD	100.0%
2023 Q4	- USD	0.0%
2023 Q1	- USD	0.0%
2023 Q2	- USD	0.0%
2022 FY	-588.71 Thousand USD	-1667.18%
2022 Q3	-1.09 Million USD	-146.03%
2022 Q2	-446.25 Thousand USD	-569.77%
2022 Q1	-66.62 Thousand USD	-15.0%
2021 Q3	-15.5 Thousand USD	-49.7%
2021 Q1	-5355.89 USD	18.91%
2021 Q4	-57.93 Thousand USD	-273.63%
2021 Q2	-10.35 Thousand USD	-93.4%
2021 FY	-33.31 Thousand USD	-43.14%
2020 FY	-23.27 Thousand USD	1.13%
2020 Q4	-6605.23 USD	25.31%
2020 Q3	-8844.00 USD	-98.47%
2020 Q2	-4456.00 USD	10.72%
2020 Q1	-4991.00 USD	-7.77%
2019 Q3	-9195.00 USD	-168.23%
2019 Q2	-3428.00 USD	11.54%
2019 Q1	-3875.00 USD	22.56%
2019 FY	-23.54 Thousand USD	26.32%
2019 Q4	-4631.00 USD	49.64%
2018 Q3	-11.23 Thousand USD	31.26%
2018 Q1	-3880.00 USD	-42.65%
2018 Q4	-5004.00 USD	55.45%
2018 Q2	-16.34 Thousand USD	-321.19%
2018 FY	-31.94 Thousand USD	-1546.75%
2017 Q2	-1941.00 USD	0.0%
2017 Q3	-9005.00 USD	-363.94%
2017 FY	-1940.00 USD	0.0%
2017 Q4	-2720.00 USD	69.79%

Peer Operating Income Comparison of Instadose Pharma Corp.

Name	Operating Income	Operating Income Difference
BioQuest Corp.	-89.76 USD	100.0%
GSRX Industries Inc.	- USD	NaN%
High Sierra Technologies, Inc.	-238.36 Thousand USD	100.0%